AstraZeneca PLC (AZN) Boasts Of Pipeline But Analysts Still Believe Deals Are A Must
2/6/2014 9:52:31 AM
AstraZeneca Plc (AZN), the U.K.’s second-biggest drugmaker, is advancing experimental drugs into late-stage clinical trials faster than expected in a bid to replace sales that it’s losing to generic competitors. Three medicines that may move into final-stage development this year have potential for peak annual sales of at least $1 billion, the London-based company said yesterday. One of those is an Alzheimer’s drug called AZD3293 that’s in early-stage testing, meaning it could skip the middle stage of human trials.
Help employers find you! Check out all the jobs and post your resume.
comments powered by